The CD47 mAb Magrolimab is initially administered using a priming dose to deplete aged RBCs susceptible to phagocytic clearance induced by CD47 blockade to avoid anemia during maintenance dosing [253,274]. The gene discussed is CD47; the disease is anemia (phenotype).